VolitionRx Limited — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. This is an annual report; the supplied filing text does not provide a clear standalone fourth-quarter income statement or other Q4 results.
Business context
VolitionRx is a clinical-stage diagnostics company developing Nu.Q tests based on measuring circulating nucleosomes and their epigenetic signals, primarily for early cancer detection. Research and development remained the principal activity; the company reported only minimal revenue. Its plans include clinical validation and regulatory clearance, initially targeting Europe and Asia, with the United States also a strategic market. It expects to commercialize through partners and distributors.
Financial performance and position
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | $17,096 | $0 |
| Operating expenses | $16.06 million | $17.90 million |
| Operating loss | $16.04 million | $17.90 million |
| Net loss | $16.10 million | $18.01 million |
| Net loss per share, basic and diluted | $0.41 | $0.57 |
| Net cash used in operating activities | $12.74 million | $14.73 million |
Revenue comprised $16,204 of services and $892 of royalties. The filing does not report a meaningful gross margin; revenue was negligible relative to operating costs. R&D expense was $10.36 million, general and administrative expense $4.73 million, and sales and marketing expense $0.97 million.
At year-end, cash and cash equivalents were $16.97 million, up from $13.43 million. Current assets were $17.56 million and current liabilities $3.86 million, implying working capital of approximately $13.70 million. Total assets were $21.29 million; total liabilities were $7.09 million; stockholders’ equity was $14.20 million. Long-term debt, including current portion, had a carrying value of $2.84 million; financing lease liabilities totaled approximately $0.71 million. Contractual payments disclosed for debt, leases, repayable grants, and collaboration commitments totaled $7.42 million, including interest where applicable.
Financing activities provided $16.93 million in cash, including $16.59 million net proceeds from common-stock issuance and $0.84 million in long-term debt proceeds, partly offset by repayments. Investing activities used $0.51 million, primarily for laboratory equipment. The company had an accumulated deficit of $89.82 million.
Changes versus FY2018
- Net loss narrowed by approximately $1.91 million, or 11%; loss per share decreased from $0.57 to $0.41. Weighted-average shares increased 25% to 39.18 million, so the per-share improvement should be considered alongside dilution.
- Operating expenses fell 10%, mainly reflecting lower G&A and R&D spending. R&D decreased 5%, while G&A and sales and marketing declined 19% and 17%, respectively.
- Operating cash use decreased by approximately $1.99 million. Management attributed the change primarily to reduced R&D activity and lower stock compensation, partly offset by higher personnel costs.
- Cash increased despite operating and investing cash outflows, principally because of equity and debt financing. Shares issued and outstanding at year-end rose to 41.13 million from 35.34 million.
- The company adopted lease-accounting Topic 842 in 2019; prior-year figures were not restated.
Outlook, risks, and unusual items
- Going concern: The auditor’s report and management state that substantial doubt exists about the company’s ability to continue as a going concern, due to recurring losses, negative operating cash flows, and minimal revenue. Continued operations depend on financing, grants, licensing proceeds, and eventual revenue; no assurance is given that funding will be available.
- Management said it would prioritize R&D personnel and facilities, primarily in Belgium, and patent rights if financing is delayed; clinical validation and regulatory timelines could then be delayed. No quantified revenue, earnings, or cash-flow guidance is provided.
- Key execution risks include clinical-study outcomes, regulatory approvals, reimbursement, market acceptance, competition, manufacturing and distribution partners, and the need for additional capital, potentially involving dilution or restrictive debt.
- Disclosure controls and internal control over financial reporting were ineffective as of year-end. Material weaknesses involved finance segregation of duties, IT oversight, and review of complex transactions. Management described remediation plans, including improved financial-reporting systems and additional finance, internal-audit, IT, and HR resources.
- In 2019, a warrant amendment involving significant stockholder Cotterford generated a $196,957 financing expense; Cotterford subsequently exercised the warrant, contributing to equity proceeds. The filing also reports a $97,981 foreign-currency translation loss in other comprehensive income.
- After year-end, Belgian Volition acquired Octamer GmbH for approximately $725,000, comprising $400,000 cash and 73,263 restricted shares, to secure supply of a reagent component. In February 2020, the University of Michigan study agreement was amended: a new study of approximately 1,800 samples was to be conducted at no additional cost, with sample collection anticipated to take up to 14 months.
- The filing reports no pending or threatened litigation expected to have a material adverse effect and no significant off-balance-sheet arrangements. It does not expect to pay dividends in the foreseeable future.
Investor facts to verify
- Whether available cash and access to new funding are sufficient to support planned studies, commercialization, and contractual obligations, and how management’s going-concern assessment evolves.
- Clinical validation results and enrollment progress for the Nu.Q colorectal cancer program, including the amended U.S. study, as well as the evidence needed for regulatory clearance.
- Progress on regulatory pathways and timelines in Europe, the United States, and other target markets, including compliance with the EU IVDR.
- Whether the identified internal-control weaknesses are remediated and whether future filings report any further deficiencies.
- Potential dilution from future equity raises, options, warrants, and other share issuances; also verify the post-year-end share count and acquisition consideration.